EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, AN2 Therapeutics's enterprise value is $-34.39 Mil.
AN2 Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-71.89 Mil. Therefore, AN2 Therapeutics's EV-to-EBITDA for today is 0.48.
The historical rank and industry rank for AN2 Therapeutics's EV-to-EBITDA or its related term are showing as below:
ANTX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -17.75 Med: 0 Max: 0.53
Current: 0.48
During the past 4 years, the highest EV-to-EBITDA of AN2 Therapeutics was 0.53. The lowest was -17.75. And the median was 0.00.
ANTX's EV-to-EBITDA is ranked better than 79.82% of 451
companies
in the Biotechnology industry
Industry Median: 9.15
vs ANTX: 0.48
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
AN2 Therapeutics EV-to-EBITDA Historical Data
The historical data trend for AN2 Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of AN2 Therapeutics's EV-to-EBITDA
For the Biotechnology subindustry, AN2 Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AN2 Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AN2 Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where AN2 Therapeutics's EV-to-EBITDA falls into.
AN2 Therapeutics's current Enterprise Value is $-34.39 Mil.
AN2 Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-71.89 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
AN2 Therapeutics's PE Ratio for today is calculated as:
AN2 Therapeutics's share price for today is $2.06.
AN2 Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.590.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of AN2 Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
AN2 Therapeutics (AN2 Therapeutics) Business Description
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ANTX has been successfully added to your 